Biochem/physiol Actions

Cell permeable: no

Primary TargetCOX-1

Reversible: yes

Product competes with ATP.

Target IC₅₀: 4.85 µM against COX-1

General description

A nonsteroidal anti-inflammatory drug (NSAID) that acts as a reversible and competitive inhibitor of cyclooxygenase 1 (COX-1) (IC₅₀ = 4.85 µM). Inhibits COX-2 at higher concentrations (IC₅₀ = 223 µM). Blocks aspirin inactivation of COX-1 (EC₅₀ antagonism of 200 µM aspirin = 290 nM). Shown to reduce the total Aβ secretion (Amyloid β_{40 and 42}) in human neuronal cells and offers neuroprotection against glutamate-, nitric oxide-, and superoxide-induced damage. Reported to activate peroxisome proliferator-activated receptors (PPAR) α and γ in both CV-1 and C3H10T1/2 cells (~100 µM-500 µM).

A nonsteroidal anti-inflammatory drug (NSAID) that acts as a reversible, competitive, non-selective cyclooxygenase (COX) inhibitor (IC₅₀ = 4.85 µM for purified COX-1 and 223 µM for purified COX-2). Also reported to inhibit COX-1 and COX-2 activity in intact bovine aortic endothelial cells (BAEC) (IC₅₀ = 7 µM for COX-1 and 72.7 µM for COX-2). Potently blocks aspirin inactivation of COX-1 (EC₅₀ antagonism of 200 µM aspirin ~290 nM for ovine COX-1). Decreases the secretion of total Aβ (Amyloid β_40&42) by human neuronal cells and offers neuroprotection against glutamate-, nitric oxide- and superoxide-induced damage. Activates peroxisome proliferator activated receptors α and γ in both CV-1 and C3H10T1/2 cells (~100 µM - 500 µM).

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Asanuma, M., et al. 2001. J. Neurochem.76, 1895.Blasko, I., et al. 2001. Neurobiol. Dis.8, 1094.Ouellet, M., et al. 2001. Proc. Natl. Acad. Sci. USA98, 14583.Casper, D., et al. 2000. Neurosci. Lett.289, 201.Lambat, Z., et al. 2000. Metab. Brain Dis.15, 249.Lim, G.P., et al. 2000. J. Neurosci.20, 5709.Ogawa, O., et al. 2000. Eur. J. Pharmacol.408, 137.Wyss-Coray, T., and Mucke, L. 2000. Nat. Med.6, 973.Lehmann, J.M., et al. 1997. J. Biol. Chem.272, 3406.Boneburg, E.M., et al. 1996. J. Clin. Pharmacol.36, 16S.Mitchell, J.A., et al. 1994. Proc. Natl. Acad. Sci. USA90, 11693.

Packaging

1 g in Plastic ampoule

Reconstitution

Following reconstitution aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Warning

Toxicity: Harmful (C)